JOE
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Journal of Endocrinology (2008) 197, 297-307       DOI: 10.1677/JOE-08-0050
© 2008 Society for Endocrinology
This Article
IMMEDIATE FREE ACCESS ARTICLE
Right arrow OA Free Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bujalska, I J
Right arrow Articles by Stewart, P M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bujalska, I J
Right arrow Articles by Stewart, P M

A novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis

I J Bujalska, L L Gathercole, J W Tomlinson, C Darimont1, J Ermolieff 2, A N Fanjul2, P A Rejto2 and P M Stewart

Division of Medical Sciences, The Medical School, Institute of Biomedical Research, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK1 Nestle Research Center, PO Box 44, Vers-Chez-Les-Blanc, 1000 Lausanne 26, Switzerland2 Pfizer Global Research and Development, La Jolla Laboratories, 10646 Science Center Drive, San Diego, California 92121, USA

(Correspondence should be addressed to P M Stewart; Email: p.m.stewart{at}bham.ac.uk)

I J B, L L G, J W T and C D declare no conflict of interest. J E, A N F and P A R are employed by Pfizer. P M S is on the advisory board for Pfizer Global R&D.

Glucocorticoid excess increases fat mass, preferentially within omental depots; yet circulating cortisol concentrations are normal in most patients with metabolic syndrome (MS). At a pre-receptor level, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activates cortisol from cortisone locally within adipose tissue, and inhibition of 11β-HSD1 in liver and adipose tissue has been proposed as a novel therapy to treat MS by reducing hepatic glucose output and adiposity. Using a transformed human subcutaneous preadipocyte cell line (Chub-S7) and human primary preadipocytes, we have defined the role of glucocorticoids and 11β-HSD1 in regulating adipose tissue differentiation. Human cells were differentiated with 1.0 µM cortisol (F), or cortisone (E) with or without 100 nM of a highly selective 11β-HSD1 inhibitor PF-877423. 11β-HSD1 mRNA expression increased across adipocyte differentiation (P<0.001, n=4), which was paralleled by an increase in 11β-HSD1 oxo-reductase activity (from nil on day 0 to 5.9±1.9 pmol/mg per h on day 16, P<0.01, n=7). Cortisone enhanced adipocyte differentiation; fatty acid-binding protein 4 expression increased 312-fold (P<0.001) and glycerol-3-phosphate dehydrogenase 47-fold (P<0.001) versus controls. This was abolished by co-incubation with PF-877423. In addition, cellular lipid content decreased significantly. These findings were confirmed in the primary cultures of human subcutaneous preadipocytes. The increase in 11β-HSD1 mRNA expression and activity is essential for the induction of human adipogenesis. Blocking adipogenesis with a novel and specific 11β-HSD1 inhibitor may represent a novel approach to treat obesity in patients with MS.




This article has been cited by other articles:


Home page
Mol. Endocrinol.Home page
N. Di Pietro, V. Panel, S. Hayes, A. Bagattin, S. Meruvu, A. Pandolfi, L. Hugendubler, G. Fejes-Toth, A. Naray-Fejes-Toth, and E. Mueller
Serum- and Glucocorticoid-Inducible Kinase 1 (SGK1) Regulates Adipocyte Differentiation via Forkhead Box O1
Mol. Endocrinol., February 1, 2010; 24(2): 370 - 380.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. W. Tomlinson, O. M. Durrani, I. J. Bujalska, L. L. Gathercole, P. J. Tomlins, T. T. Q. Reuser, G. E. Rose, S. J. Curnow, P. M. Stewart, E. A. Walker, et al.
The Role of 11ss-Hydroxysteroid Dehydrogenase 1 in Adipogenesis in Thyroid-Associated Ophthalmopathy
J. Clin. Endocrinol. Metab., January 1, 2010; 95(1): 398 - 406.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. S. Cooper and P. M. Stewart
11{beta}-Hydroxysteroid Dehydrogenase Type 1 and Its Role in the Hypothalamus-Pituitary-Adrenal Axis, Metabolic Syndrome, and Inflammation
J. Clin. Endocrinol. Metab., December 1, 2009; 94(12): 4645 - 4654.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Anagnostis, V. G. Athyros, K. Tziomalos, A. Karagiannis, and D. P. Mikhailidis
The Pathogenetic Role of Cortisol in the Metabolic Syndrome: A Hypothesis
J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 2692 - 2701.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
S. Senesi, P. Marcolongo, I. Manini, R. Fulceri, V. Sorrentino, M. Csala, G. Banhegyi, and A. Benedetti
Constant expression of hexose-6-phosphate dehydrogenase during differentiation of human adipose-derived mesenchymal stem cells
J. Mol. Endocrinol., September 1, 2008; 41(3): 125 - 133.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Society for Endocrinology.